Compare Five Below Inc (FIVE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Five Below Inc trades at $218.95 (market cap $11.75B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Five Below Inc is far larger — about 2.4× Travere Therapeutics Inc. Common Stock's market cap, and Five Below Inc is more actively traded (742,657 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FIVE | TVTX | |
|---|---|---|
Market Cap | $11.75B | $4.88B |
Volume | 742,657 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $67.52 |
52-Week Low | $147.05 | $26.79 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $12.60B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $218.95, up 2.51% today, with strong earnings momentum after beating Q1 and Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600M buyback and digital marketing push. Revenue growth accelerated from $3.6B in 2024 to $3.9B in 2025, with projected $5.3B in 2026.
FIVE presents a growth opportunity with analyst consensus target of $298.44 (36% upside), though execution risks remain. The premium valuation (P/E 19.14) requires sustained margin expansion amid consumer spending pressures. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near resistance at $219 suggests near-term consolidation.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
